U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
BOSTON, April 05, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that clinical data from the ongoing Phase 2 study of its lead product candidate A4250 in children with cholestatic liver disease has been selected by the European Association for the Study of the Liver (EASL) for an oral presentation during the late breaker session at The International Liver Congress™ (ILC) 2017 being held April 19-23, 2017, at the RAI Amsterdam in Amsterdam.
Details of the presentation are as follows:
Title: The Ileal Bile Acid Transport inhibitor A4250 decreases pruritus and serum bile acids in cholestatic liver diseases – an ongoing multiple dose, open-label, multicentre study
Session: Late Breaker
Date / Time: Saturday, April 22, 4:45 p.m. – 5:00 p.m. CET
Location: Hall 5
Presenter: Dr. Ulrich Baumann, Professor of Pediatric Gastroenterology and Hepatology at Hannover Medical School, Germany
EASL’s ILC, now in its 52nd year, is a multi-disciplinary scientific Congress which brings more than 10,000 clinicians and scientists together annually to discuss clinical innovation and research. For more information about the conference, visit https://ilc-congress.eu/.
About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit http://www.albireopharma.com.
Source: Albireo Pharma, Inc.
Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson 6 Degrees 980-938-0260 [email protected]
